Developments towards antiviral therapies against enterovirus 71.
about
Anti-Enterovirus 71 Agents of Natural ProductsPotential Antiviral Agents from Marine Fungi: An OverviewEarly detection for cases of enterovirus- and influenza-like illness through a newly established school-based syndromic surveillance system in Taipei, January 2010 ~ August 2011Deferoxamine compensates for decreases in B cell counts and reduces mortality in enterovirus 71-infected mice.Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1.Inhibition of enterovirus 71 by adenosine analog NITD008In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model.Antiviral effects against EV71 of pimprinine and its derivatives isolated from Streptomyces spEnterovirus infections of the central nervous system.Chlorogenic acid inhibits the replication and viability of enterovirus 71 in vitroResveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-κB signaling pathway.The role of Misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71.Host factors in enterovirus 71 replicationBenserazide, the first allosteric inhibitor of Coxsackievirus B3 3C protease.An enterovirus 71 strain causes skeletal muscle damage in infected mice.Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses.Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents.Chebulagic acid, a hydrolyzable tannin, exhibited antiviral activity in vitro and in vivo against human enterovirus 71.Human IgG Fc promotes expression, secretion and immunogenicity of enterovirus 71 VP1 protein.Antiviral activity of micafungin against enterovirus 71.Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry.Human genome-wide RNAi screen reveals host factors required for enterovirus 71 replication.Time series analysis of hand-foot-mouth disease hospitalization in Zhengzhou: establishment of forecasting models using climate variables as predictors.Viral and host factors that contribute to pathogenicity of enterovirus 71.Flos Farfarae Inhibits Enterovirus 71-Induced Cell Injury by Preventing Viral Replication and Structural Protein Expression.Prediction of signaling pathways involved in enterovirus 71 infection by algorithm analysis based on miRNA profiles and their target genes.In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide.Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.Dominant CD4-dependent RNA-dependent RNA polymerase-specific T-cell responses in children acutely infected with human enterovirus 71 and healthy adult controls.In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection.Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study.Antiviral activity of GuiQi polysaccharides against enterovirus 71 in vitro.Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16
P2860
Q26786981-8DAC2973-ADF3-49C4-ACCC-59BEEEC7746AQ26800107-CD0818A3-8300-40C2-BACA-51ECD54AF10FQ30373706-C91F94D6-2782-4703-8712-7AAE4BB53935Q33963572-C757FFB4-9821-46B2-B0AE-62B5EC7ABC54Q34259967-0D037369-D6CE-4539-8060-FB7AC5AA524AQ34261488-4E179BE2-BE64-4551-A63F-18C4C6BFCB21Q34287387-2311B9E3-ACBB-4D7A-AA91-70DFAEEC5940Q34620354-1465E454-956C-411A-9208-BA4B4CA20AC0Q34697319-377A2F1C-CF2D-470B-8895-9786AB183D4DQ35010174-565590F1-3DA4-4116-9749-5198ECD2D6EAQ35097865-6B2D7D53-3541-4746-AFB8-589CD27F9C05Q35154777-B3E4042C-9283-42E4-B90B-440B8BA823ABQ35383186-CCB40824-F857-47B9-A363-907585B5B6FBQ35645639-FA58F6F6-30A8-41D6-8BF5-F79D73292E58Q35740892-8297C39D-B47C-45CF-885D-16FD40B83B2BQ35880074-C1D2DCB6-89E1-4955-8850-536A9B2A4E76Q36238077-E746E765-6785-44AD-979D-F3E17DB11BB1Q36913627-9A00A914-9BE9-4936-9EAD-21ED52FE3BC1Q36947214-E83F468C-F8C6-440A-A9F6-7FAEC447D6B5Q37002620-960F238F-28B0-4EE8-9E46-3B7F2A97FB47Q37243489-A5EC41A6-CABA-455C-B114-D594FC9C339DQ37352243-C7F853CA-8D32-4254-A1DA-41D476EDDCDEQ37539365-243DE933-3C98-4638-B127-6169929D26E0Q37996089-F69B2350-704A-4531-A366-E85F4EC35FD6Q38715188-BD7C5BC2-4F79-449B-838A-26BE65A3CA3DQ38950180-5B1B20BB-A637-481B-A1AE-A947A1EAB58AQ39001868-9C7AFDD6-40EF-4D68-854A-8FDB190C4506Q39253638-040662E4-3589-4939-A1AF-8AEE8C7B6B44Q39296711-4CB5BD76-0CDE-4907-82E2-0ADECCD3DE94Q39412134-5C76C836-D913-4C92-A8C2-D515B33B9F52Q41404590-586239F6-F14D-44FF-9F1C-77242B60D8EDQ42254382-CA920B24-9F1B-4367-839D-551C3941BDF1Q57096427-4B8F6F77-5F1B-4DE2-9D21-7D1CCB75475E
P2860
Developments towards antiviral therapies against enterovirus 71.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Developments towards antiviral therapies against enterovirus 71.
@ast
Developments towards antiviral therapies against enterovirus 71.
@en
type
label
Developments towards antiviral therapies against enterovirus 71.
@ast
Developments towards antiviral therapies against enterovirus 71.
@en
prefLabel
Developments towards antiviral therapies against enterovirus 71.
@ast
Developments towards antiviral therapies against enterovirus 71.
@en
P2093
P1433
P1476
Developments towards antiviral therapies against enterovirus 71.
@en
P2093
Justin J H Chu
Mary M-L Ng
P304
P356
10.1016/J.DRUDIS.2010.10.008
P577
2010-10-23T00:00:00Z